# DESTINY-Gastric03 (NCT04379596)

> Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

No report yet. It can be ordered.

- Drugs tested: trastuzumab deruxtecan; trastuzumab deruxtecan plus durvalumab; trastuzumab deruxtecan plus pembrolizumab
- Indication: advanced HER2-expressing gastric cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04379596
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Gastric Cancer
- Interventions: Fluorouracil (5-FU); Capecitabine; Durvalumab; Oxaliplatin; Trastuzumab; Trastuzumab deruxtecan; Cisplatin; Pembrolizumab; Volrustomig; Rilvegostomig
- Enrollment: 452
- Primary outcome: Part 1: Occurrence of adverse events (AEs) and serious adverse events (SAEs), graded according to NCI CTCAE v5.0
- Primary outcome: Part 1: Ocurrence of dose-limiting toxicities (DLTs)
- Primary outcome: Part 1: Changes from baseline in laboratory parameters
- Primary outcome: Part 1: Changes from baseline in vital signs
- Primary outcome: Part 1: Changes from baseline in electrocardiogram (ECG) results
- Primary outcome: Part 2, Part 3, Part 4 and Part 5: Endpoint assessed by Investigator per RECIST v1.1: Confirmed Objective Response Rate (ORR)

## Indexed commentary on DESTINY-Gastric03 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 37
- Podcasts: 29
- X threads: 13
- Bluesky threads: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=destiny-gastric03-nct04379596

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04379596", "email": "<work email>"}; the inbox owner confirms by the emailed link.